Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 59

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 59
---
 Year | — |     | Total Average 
 Equity Award  
 Adjustments - 
 NEOs ($)      |   794,516 |     |    |
|:-----|:----|:---------------------------------------------------------------------|----------:|:----|---:|:-----------------------------------------------------------------------------------------------------------------------------|:---------|:--|:----|:------------------------------------------------------------------------------------------|:--------|:----|:----------------------------------------------------------------------------------------------------------------------------------|:---------|:--|---:|:---------------------------------------------------------------------------------------------------------------------------------------------------|:---------|:--|---:|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:----|:--------------|----------:|:----|---:|
| 2023 |     | $                                                                    | 1,237,300 |     | -8 | $                                                                                                                            | —        |   |     | $                                                                                         | —       |     | $                                                                                                                                 | (124,334 | ) | -8 | $                                                                                                                                                  | (107,985 | ) | -8 | $                                                                                                                                                                                   | — |     | $             | 1,004,981 |     | -8 |

(5) This column represents cumulative Company total shareholder return (“TSR”) and is calculated by assuming that a $100 investment was made on the day prior to the first fiscal year reported and reinvesting all dividends until the last day of each reported fiscal year.

(6) This column represents cumulative peer group TSR computed in accordance with Note 5. The peer group used for this purpose is the following published industry index: Nasdaq Biotech Index.

(7) The dollar amounts reported in column (i) represent the amount of net income (loss) reflected in the Company’s audited financial statements for the applicable year.

(8) Due to administrative errors in the calculations, the 2023 amounts reported in the Company's proxy statement filed on April 29, 2024 have been corrected.

(9) We determined total net revenue to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2024. This performance measure may not have been the most important financial performance measure for previous years, and we may determine a different financial performance measure to be the most important financial performance measure in future years.

Financial Performance Measures As described in greater detail in the Compensation Discussion and Analysis section of this Proxy Statement, the Company’s executive compensation program reflects a pay-for-performance philosophy. The metrics that the Company uses for both our long-term and short-term incentive awards are selected based